1 in 4 ER Patients Refuse Buprenorphine in Medical Detox Study

Nearly one in four emergency department patients with opioid use disorder declined buprenorphine when it was offered to them during medical detox, according to a new study published in JAMA Network Open. The findings point to specific, fixable barriers, above all fear of precipitated withdrawal, rather than a lack of desire to stop using opioids.

Researchers interviewed 82 adults at four emergency departments in South Carolina, Michigan and Ohio. While 77 percent accepted emergency department-initiated buprenorphine, the 23 percent who declined gave reasons that clinicians can directly address, the authors said.

Why Medical Detox Matters

Withdrawal is often the crisis that brings people with opioid use disorder to the emergency department in the first place, and it is the moment when medication can change the course of an overdose epidemic that killed roughly 87,000 Americans between October 2023 and September 2024. Buprenorphine reduces all-cause mortality in opioid use disorder, lowers overdose risk and, when started in the emergency department, doubles retention in treatment at 30 days.

Yet acceptance rates for emergency department-initiated buprenorphine vary widely across studies, from 43 to 86 percent. Understanding why patients say no is a necessary step toward closing the gap between a medication that works and patients who never start it.

What the Study Found

The most common reason patients gave for declining was concern about precipitated withdrawal or adverse effects, cited by 50 percent of those who described reasons for refusing. Many had lived through it before. “It put me into precipitated withdrawal,” one participant said. “It was miserable, miserable. That’s something I don’t want to do again.”

Another 32 percent did not want to become physically dependent on buprenorphine, framing the medication as trading one addiction for another rather than a bridge out of opioid use. And 23 percent faced housing and logistical barriers, including recovery residences and shelters that prohibit buprenorphine, forcing a choice between medication and a bed. “If I had my own house, my own place to live I would have had more decisions to make on my own,” one participant said, “because when you go to treatment, nobody lets you take suboxone at rehab.”

Patients who accepted gave equally concrete reasons. Relief from opioid withdrawal topped the list at 69 percent, followed by a desire to be substance free (39 percent), wanting a normal life again (28 percent), fear of overdose or death (24 percent) and caring for children (13 percent). “I know I need something to help me with these withdrawals,” one acceptor said.

The study also upended an assumption. Treatment readiness scores were nearly identical between those who accepted and those who declined, meaning declination was not driven by ambivalence. Patients with more than a high school education were actually more likely to decline, a finding the authors said warrants further research.

Understanding Buprenorphine and Precipitated Withdrawal

Buprenorphine is a partial opioid agonist, meaning it activates the same receptors as heroin or fentanyl but to a lesser degree. In detox, it relieves withdrawal and cravings without producing the same high. The catch is pharmacological: if taken while full opioids still occupy the receptors, buprenorphine displaces them and triggers precipitated withdrawal, a sudden and severe onset of symptoms.

Proper induction timing prevents this. In the study sites, observed in-ED dosing required a Clinical Opiate Withdrawal Scale score above 8, and patients with milder withdrawal could take home a prescription for unobserved induction. Low-dose induction protocols, which start with small amounts and scale up, are another option for fentanyl-era patients whose withdrawal patterns are less predictable.

For patients whose fear of precipitated withdrawal blocks buprenorphine entirely, methadone is a full agonist that can be started at any point in withdrawal without triggering the reaction, and long-acting injectable buprenorphine offers another path. Giving patients a menu of options, the authors argue, responds directly to the concerns patients described.

Levels of Detox Care Explained

Emergency departments function as a low-barrier entry point to medical detox, particularly for people with unstable housing, a group that made up 51 percent of study participants. For people who need more structure, clinically managed residential programs and medically monitored inpatient detox provide 24-hour support during withdrawal. Medication-assisted treatment with methadone or buprenorphine remains the evidence-based standard of care at every level.

Finding Medical Detox

The study’s message for treatment seekers is that declining buprenorphine once does not close the door. Precipitated withdrawal is preventable with correct induction timing, dependence concerns can be addressed with honest counseling, and medication should never cost someone their housing. If you or someone you love needs help with opioid withdrawal, Detox.com lists medical detox centers and detox programs near you that offer medication-assisted treatment. Call 800-671-4304 to find a medically supervised detox program.

Opioid withdrawal is rarely life-threatening on its own, but untreated withdrawal drives relapse, and returning to opioids after even a short break sharply raises overdose risk because tolerance drops. Never attempt to detox from opioids alone. Alcohol and benzodiazepine withdrawal can be fatal without medical supervision.